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Abstract
Pancreatic carcinoma has an extremely bad progno-
sis due to lack of early diagnostic markers and lack
of effective therapeutic strategies. Recently, we have
established an in vitro model recapitulating the first
steps in the carcinogenesis of the pancreas. SV40
large T antigen–immortalized bovine pancreatic duct
cells formed intrapancreatic adenocarcinoma tumors
on k-rasmut transfection after orthotopic injection in
the nude mouse pancreas. Here we identified genes
and proteins differentially expressed in the course of
malignant transformation using reciprocal suppres-
sion subtractive hybridization and 2D gel electrophore-
sis and mass spectrometry, respectively. We identified
34 differentially expressed genes, expressed sequence
tags, and 15 unique proteins. Differential expression
was verified for some of the genes or proteins in sam-
ples from pancreatic carcinoma. Among these genes
and proteins, the majority had already been described
either to be influenced by a mutated ras or to be dif-
ferentially expressed in pancreatic adenocarcinoma,
thus proving the feasibility of our model. Other genes
and proteins (e.g., BBC1, GLTSCR2, and rhoGDIa),
up to now, have not been implicated in pancreatic
tumor development. Thus, we were able to estab-
lish an in vitro model of pancreatic carcinogenesis,
which enabled us to identify genes and proteins dif-
ferentially expressed during the early steps of malig-
nant transformation.
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Introduction
Pancreatic cancer is the fourth most common cause of
cancer deaths [1]. Its incidence is increasing, affecting
about 10 per 100,000 population per year in western
countries. Because no screening markers are available up
to now and due to lack of early symptoms, the majority of
tumors are already in advanced nonresectable stages at the
time of diagnosis, and no therapeutic strategy developed so far
has resulted in a considerable increase in long-term survival.
This is why the prognosis of this disease is still very dismal, with
5-year survival rates of < 5% [2]. An important approach to the
understanding of the biology and molecular alterations involved
in the carcinogenesis of this disease is the development of
relevant in vitro and in vivomodels. These models may provide
new diagnostic tools that would allow diagnosis at earlier
stages, and this in turn may result in an increase in long-term
survival. Because most pancreatic tumors are of ductal pheno-
type [3] and may derive from ductal epithelial cells [4], the
cultivation of isolated human pancreatic duct epithelial cells
may play a crucial role in the development of an in vitro model
for pancreatic carcinogenesis.
In recent years, numerous alterations associated with car-
cinogenesis have been identified, namely, mutation of the
ki-ras oncogene. More than 90% of pancreatic adenocar-
cinomas harbor mutations of this gene; these mutations are
detectable as well in early stages of tumor development (PanIN
lesions) [5], as in metastatic tumors. Thus, mutation of the
ki-ras oncogene seems to be an early and important event in
the tumorigenesis of the pancreas.
Recently, we were able to establish an in vitro model by
mimicking the first steps of the carcinogenesis of the pancreas.
We immortalized bovine pancreatic duct cells through trans-
fection with SV40 large T antigen. These immortal cells were
then transfected additionally with a vector coding for a mutated
ki-ras gene (codon 12: GGT!GTT). Both cell lines were
characterized in detail and showed classic markers of differ-
entiated pancreatic duct cells [carbonic anhydrase type II,
cytokeratins (CK) 7 and 19, and others], but they exhibited
Address all correspondence to: R. Jesenofsky (R. Jesnowski), Clinical Cooperation Unit
Molecular Gastroenterology (E180), German Cancer Research Center, Im Neuenheimer Feld
581, Heidelberg D-69120, Germany. E-mail: r.jesenofsky@dkfz.de
1This article refers to supplementary material, which is designated by ‘‘W’’ (i.e., Table W1) and
is available online at www.bcdecker.com.
Received 22 November 2006; Revised 15 January 2007; Accepted 16 January 2007.
Copyright D 2007 Neoplasia Press, Inc. All rights reserved 1522-8002/07/$25.00
DOI 10.1593/neo.06754
Neoplasia . Vol. 9, No. 2, February 2007, pp. 136 –146 136
www.neoplasia.com
RESEARCH ARTICLE
marked differences in their tumorigenic potential. Although
the only immortalized cell line was neither able to grow in soft
agar nor able to induce tumor, mutated ki-ras–expressing
cells grew in soft agar and formed tumors and liver metas-
tases when inoculated orthotopically in the pancreas of nude
mice [6]. In an attempt to characterize the transition from an
almost benign cell lineage to an invasive ductal adenocarci-
noma, we asked for changes in gene expression at both RNA
and protein levels. Here we describe the analysis and
identification of genes and proteins that are differentially
expressed during this course of malignant transformation.
Materials and Methods
RNA Isolation
Total RNA was prepared from pancreatic tissue samples,
using the ToTally RNA kit (Ambion, Inc., Austin, TX), ac-
cording to the protocol supplied by the manufacturer. RNA
from pancreatic cell lines VA and VArasmut was isolated with
RNeasy mini kit (Qiagen, Inc., Hilden, Germany) following
the manufacturer’s recommendations. For suppression sub-
tractive hybridization (SSH) analysis, total RNA was treated
with Dnase I (Ambion, Inc.) to remove traces of genomic
DNA. Poly A+ RNA was isolated from total RNA preparations
using oligo(dT)-conjugated magnetic Dynabeads (Dynal Bio-
tech, Oslo, Norway).
SSH
SSH was performed using the PCR-Select cDNA Sub-
traction Kit (BD Clontech, Heidelberg, Germany). VArasmut
and VA RNA isolations were reciprocally compared by for-
ward and reverse subtractions. Driver and tester cDNA were
produced, each from 2 mg of Poly A+ RNA, following the
manufacturer’s guidelines. Synthesized cDNA were digested
with the restriction enzyme RsaI, and tester cDNA popula-
tions were divided into two tubes and ligated to adaptor 1 or
adaptor 2R. Subtractive hybridization was performed by
adding 1.5 ml of driver cDNA to each tube, one containing
1.5 ml of adaptor 1 and the other containing 1.5 ml of adapter
2R–ligated diluted tester cDNA in 1 ml of 4 hybridization
buffer. After denaturation, samples were allowed to anneal at
68jC for 8 hours. Following the first hybridization, the two
samples were combined simultaneously with the addition of
1 ml of freshly denatured driver cDNA, and hybridization was
continued overnight at 68jC. Products from the second hy-
bridization were diluted in 200 ml of dilution buffer (20 mM
HEPES pH 8.3, 50 mM NaCl, and 0.2 mM EDTA), heated at
68jC for an additional 7 minutes, and stored at 20jC.
Polymerase Chain Reaction (PCR) Amplification
of Subtracted Products
PTC-200 Thermal Cycler (MJ Research, Waltham, MA)
was used to perform PCR amplification of subtracted tester
products. Primary PCR amplifications were conducted for
each tester using diluted subtracted products following the
second hybridization. One microliter of sample was added
to 24 ml of PCR master mix prepared using the reagents
supplied in the kit, and cycling conditions commenced as
follows: 75jC for 5 minutes to extend the adaptors; 94jC for
25 seconds; and 27 cycles at 94jC for 10 seconds, 66jC for
30 seconds, and 72jC for 1.5 minutes. Amplified products
were diluted 10-fold in sterile water, and 1 ml of diluted primary
PCR products was added to 24 ml of secondary PCR master
mix containingnestedprimers (1and2R) to ensure the specific
amplification of double-stranded templates containing both
adaptors. Secondary PCR was performed at 94jC for 10 sec-
onds, 68jC for 30 seconds, and 72jC for 1.5 minutes (cycle
numbers were 18 and 19 for VArasmut and VA, respectively).
PCR products were analyzed on a 2% agarose gel.
Cloning of Subtracted cDNA Templates
Following secondary PCR amplification, subtracted prod-
ucts from each tester cDNA population were purified using
the QIAquick PCR Purification Kit (Qiagen, Inc.). Thus, short
DNA fragments below 100 bp were removed before cloning.
Purified products were ligated with the pGEM T-Easy vector
(Promega Corp., Madison, WI) and used for the electro-
transformation of competent DH5a Escherichia coli cells.
Colonies were grown in a selective LB agar medium con-
taining X-gal and isopropyl b-D-1-thiogalactopyranoside
(IPTG) for the screening of blue/white colony. For each
tester, 384 colonies were randomly picked up in microtiter
plates and grown overnight in a liquid LB medium.
Differential Screening By Microarray Hybridization
To confirm the unique expression of subtracted products,
all cDNA clones were subjected to differential screening by
microarray hybridization. First, inserts from 768 selected
clones (384 clones for each tester) were PCR-amplified with
T7 and SP6 primers. PCR was performed by adding 0.5 ml of
saturated growth liquid culture to 100-ml PCRs containing
10 mM Tris (pH 9.0), 50 mM KCl, 150 mM dNTP, 3 M betaine,
30 mM cresol red, and 2.0 U of Taq DNA polymerase (MBI
Fermentas, St. Leon-Rot, Germany) in 96-well plates. Thermal
cycling conditions consisted of initial denaturation at 95jC
for 3 minutes, followed by 35 cycles of denaturation at 95jC
for 30 seconds, annealing at 53jC for 30 seconds, and elon-
gation at 72jC for 3 minutes, with a final 10-minute extension
at 72jC in PTC-200 Thermal Cycler (MJ Research). Five
microliters of each PCR was examined on a 2% agarose gel.
PCR fragments were purified by isopropanol precipitation.
SSH products from both subtraction experiments were
combined on a slide. Quadruplicate spotting onto a custom-
madepoly-L-lysine surfacewas carried out with SDDC-2DNA
Microarrayer (Engineering Services, Inc., Toronto, Canada),
using betaine spotting solution, according to the protocol
described previously [7]. Poly A+ RNA isolated from VArasmut
and VA cells (0.5 mg each) was labeled by direct incorporation
of either Cy3 or Cy5 fluorescent dye using SuperScript II
reverse transcriptase (Invitrogen, Inc., Karlsruhe, Germany)
and oligo-d(T)20 as a primer. Labeled probes were purified
through QIAquick PCR purification columns (Qiagen, Inc.),
dried in a SpeedVac (Qiagen, Inc.), and resuspended in a
total volume of 16 ml of hybridization buffer [3 SSC (0.45 M
NaCl, 0.045 M sodium citrate), 1% sodium dodecyl sulfate
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(SDS), 5 Denhardt’s solution, 100 mg/ml sheared salmon
sperm DNA, 50% formamide, and 10% dextran sulfate]. The
probes were denatured at 80jC for 10 minutes and applied
to arrayed/denatured slides at 45jC for 16 hours in a hu-
midified chamber (Telechem, Inc., Sunnyvale, CA). Hybrid-
ized slides were washed in 2 SSC and 0.1% SDS for
5 minutes at room temperature and in 0.2 SSC for 5 min-
utes before scanning by the ScanArray 5000 Microarray
Analysis System (GSI Lumonics, Inc., Watertown, MA).
Separate images with 10-mm resolution were captured for
each of two fluorophores used. GenePix v. 4.0 (Axon Instru-
ments, Inc., Union City, CA) software was used to quanti-
tate signals at each spot. Signal intensity filtering and
background signal correction for spots were performed
using GP3 perl script (http://www.bch.msu.edu/~zacharet/
microarray/gp3.html) [8].
Feature spot signals were normalized relative to signals
from external controls: Arabidopsis thaliana genes spotted
on arrays together with SSH PCR products (the corre-
sponding Arabidopsis mRNA was spiked into labeling re-
actions in known concentrations).
The mean ratios of Cy3 and Cy5 signal intensities for
individual spots were calculated by averaging the data
obtained in four independent hybridizations with ‘‘dye
flip.’’ Genes were considered differentially expressed
when all hybridizations showed a > 2-fold change. The se-
quencing of PCR products was performed at Genotype, Inc.
(Hirschhorn, Germany), a company providing commercial
DNA analysis service.
Homology searches were performed using the Basic
Local Alignment Search Tool (BLAST) on the combined
GenBank/EMBL nonredundant (nr), expressed sequence
tag (EST), and SwissProt databases (National Center for
Biotechnology Information, which can be accessed online at
www.ncbi.nlm.nih.gov).
Two-Dimensional Gel Electrophoresis
Protein extraction from cells obtained from different
passages was performed with 1 ml of lysis buffer (9.5 M
urea, 2% 3-[(3-Cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS), 0.8% Pharmalyte 3-10, 1%
dithiothreitol (DTT), and 5 mM Pefabloc SC PLUS; Roche
Diagnostics, Inc., Mannheim, Germany). After centrifugation
at 13,000g at 15jC for 60 minutes, the protein solution was
collected and stored at 80jC until use. Protein concentra-
tion was determined by the Bio-Rad Protein Assay (Bio-Rad,
Munich, Germany), using a UV/Visible spectrophotometer
(Utrospec 2000; Pharmacia Biotech, Uppsala, Sweden).
Samples (protein concentration, f 1–3 mg/ml) were
loaded into linear immobilized gradient (IPG) strips (Immobi-
line DryStrips, pH 4–7; Amersham Biosciences, Freiburg,
Germany) using 50 mg of total protein per strip. The IPG
strips were rehydrated (10 hours, 30 V, and 20jC) in a
solution (350 ml) of 8 M urea, 2% CHAPS, 0.5% IPG buffer
pH 4–7, 16 mM DTT, and a calculated amount of protein
sample. Separation in the first dimension was performed on
an IPGphor unit (Amersham Biosciences). The IPG strips
were focused for a total of 125 kV hour. Before the second
dimension separation, the IPG strips were equilibrated in
equilibration buffer twice for 20 minutes (50 mM Tris–HCl
pH 8.8, 6 M urea, 30% glycerol, and 2% SDS) containing
DTT (10 mg/ml) and iodoacetamide (40 mg/ml), respectively.
The second dimension [SDS polyacrylamide gel electro-
phoresis (PAGE)] was performed on laboratory-made poly-
acrylamide gels (12.5% T; 1.5  200  250 mm) running on
a vertical Hoefer DALT Electrophoresis Tank (Amersham
Biosciences). Electrophoresis was carried out for about
22 hours in TGS electrode buffer (25 mM Tris, 192 mM gly-
cine, and 0.1% SDS pH 8.3) at 10jC, applying a constant
voltage of 85 V.
Gel Analysis
2-DE separated protein spots were visualized with a
modified silver-staining method compatible with matrix-
assisted laser desorption/ionisation–time of flight–mass
spectrometry (MALDI-TOF-MS) [9]. Silver-stained gels were
digitized using a GS-800 densitometer (Bio-Rad), and
images were imported in a 2D gel image analysis program
on a set of six gels per sample. PDQuest 7.1 (Bio-Rad) was
used to locate and quantify protein spots and to match spots
through the gels. The quantity of each protein spot was
normalized against the total quantity arising from all valid
protein spots on the gel. Statistical comparison between
individual protein abundances was conducted by the calcu-
lation of Student’s t test within the PDQuest analysis, with a
significance level of at least 90%.
Protein Identification By MALDI-MS
Gel pieces containing proteins of interest were manually
excised and subjected to in-gel digestion. Proteins were
reduced, alkylated, and digested with sequencing-grade
modified trypsin (Promega Corp.) using 10 ml of trypsin
(10 ng/ml in 40 mM NH4HCO3). Tryptic digested MALDI
samples were prepared by cocrystallization of a saturated
solution of the matrix (a-cyano-4-hydroxycinnamic acid in
50/50 vol/wt.% acetonitrile/0.1% trifluoroacetic acid in water)
with ZipTipC18 (Millipore, Inc., Schwalbach, Germany) con-
centrated samples.
MALDI mass fingerprint spectra were recorded in positive
ion mode with delayed extraction with a Reflex II TOF instru-
ment (Bruker Daltonics, Inc., Bremen, Germany). Calibration
was performed internally by a two-point linear fit using
the autolysis products of trypsin at m/z = 1045.56 and
m/z = 2211.10. Tryptic monoisotopic peptide masses were
searched against NCBInr and SwissProt databases using
the Mascot (Matrix Science, Ltd., London, Great Britain) and
ProFound (Rockefeller University, New York, NY) programs.
Verification of Differential Gene and Protein Expression
in Chronic Pancreatitis and Pancreatic Adenocarcinoma
To verify that the differential gene expression identified in
our model system holds true in vivo, the expression of se-
lected genes was analyzed in samples from normal pancre-
as, chronic pancreatitis, and pancreatic adenocarcinoma,
using semiquantitative reverse transcription (RT) PCR.
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Intron spanning primers for the respective genes (Table 1)
were designed, using the online software Primer3 (www.
broad.mit.edu/cgi-bin/primer/primer3_www.cgi), to identify
possible genomic DNA contamination. To ensure that the
PCR was in its logarithmic phase, the appropriate cycle
number for each single gene was determined in prior experi-
ments. PCR conditions were as follows: 94jC for 15 minutes,
cycling at 94jC for 45 seconds, 60jC for 45 seconds, and
72jC for 1 minute, followed at the end by an extension step
at 72jC for 10 minutes.
The differential protein expression of annexin 1 was ana-
lyzed by immunohistochemistry in paraffin-embedded tissue
samples obtained from resections due to chronic pancreati-
tis and pancreatic carcinoma using standard protocols. In
brief, tissue sections were deparaffinized in xylene (2 
5 minutes), rehydrated in a graded series of ethanol, blocked
with 10% fetal calf serum, and incubated for 45 minutes
with anti–annexin 1 antibody [1:100 in phosphate-buffered
saline (PBS)–bovine serum albumin (BSA); Santa Cruz Bio-
technology, Santa Cruz, CA]. After incubation with the second
antibody (rabbit–anti-mouseHRP, 1:100, inPBS–BSA;Dako,
Inc., Hamburg, Germany), slides were developed using
AEC substrate (Chemicon, Hampshire, Great Britain).
Results
Genes Differentially Expressed in ras-Transformed
Pancreatic Duct Epithelial Cells
The secondary SSH PCR resulted in a distinct banding
pattern and low background. Cloned subtraction SSH prod-
ucts were PCR-amplified and robotically spotted on micro-
arrays along with normalization control DNA. The microarrays
were hybridized with Cy5/Cy3–labeled RNA isolated from
VArasmut and VA cells. After statistical analysis of hybridization
results, 65 clones were considered differentially expressed
and sequenced. Among these, 28 unique genes and 6 ESTs
were identified; 16 of them were upregulated and 18 were
downregulated in VArasmut cells. The results of the BLAST
homology search are presented in Table 2. Of the 28 anno-
tated genes, 14 already had been described to be either
influenced by a mutated ras or differentially expressed in
pancreatic adenocarcinoma (Table 2), thus proving the val-
idity of our model. Other genes (e.g., epsin 1, apolipoprotein
A1), up to now, have not been implicated in ras signaling.
Most of the upregulated genes accounted for proteins of the
cytoskeleton-like 40-kDa keratin, CK7, CK18, CK19, and
myosin regulatory light chain. Moreover, several extra-
cellular matrix proteins, as Col Ia1, Col Va2, and osteo-
nectin/SPARC, were upregulated. Additionally, two ribosomal
proteins (mRPS34 and RPL26) and a enolase were up-
regulated. In contrast, the downregulated genes composed
a rather heterogeneous group. Thus, three ribosomal pro-
teins (RPS5, RPS19, and RPL39) and two putative tumor-
suppressor genes, breast basic conserved 1 (BBC1) and
GLTSCR2, were downregulated. Additionally, two genes in-
volved in tumor immunology/tumor rejection, major histo-
compatibility complex (MHC) class 1 protein molecule D18.3
and SCART1, were downregulated. For the remaining down-
regulated genes (Table 2), no grouping concerning functional
criteria was possible.
Proteins Regulated By Activated ras in Pancreatic
Duct Cells (PDCs)
Identification of proteins from 2D gels of VA and VArasmut
cell lysates obtained from four independent experiments was
conducted by MALDI mass fingerprinting. At the protein
level, 36 protein spots were identified by mass spectrometry,
representing 22 unique proteins (TableW1 and Figure 1). For
several proteins [heat shock protein (HSP) 70, actin, vimen-
tin, CK8, and CK19], different isoforms or fragmented pro-
teins (CK8 and tubulin) were identified. Of the 36 analyzed
protein spots, 11 were found to be upregulated and 9 were
found to be downregulated in the majority of experiments
by at least 1.5-fold in VArasmut cells (Table 3), whereas for
the remainder, the expression was unchanged or expres-
sion changes were inconsistent. These 20 differentially ex-
pressed protein spots represented 15 unique proteins. Also
at the protein level, several proteins (b actin, annexin 1,
CK8, HSP70, myosin regulatory light chain, and vimentin)
already had been demonstrated to be differentially ex-
pressed in pancreatic adenocarcinoma, again proving the
validity of our model. Additionally, tropomyosin 1, fragmented
a tubulin, g actin, and proliferating cell nuclear antigen
(PCNA) were found to be downregulated, whereas stress-
induced phosphoprotein 1, HSP27, Grp58, rho guanine
dinucleotide phosphate dissociation inhibitor a (rhoGDIa),
and fragmented b tubulin were upregulated in VArasmut cells.
Verification of Differential Gene and Protein Expression
in Chronic Pancreatitis and Pancreatic Adenocarcinoma
We attempted to verify the differential gene expression
identified in our model system in vivo; thus, the expression
of selected genes and proteins was analyzed in samples
from normal pancreas, chronic pancreatitis, and pancreatic
adenocarcinoma using semiquantitative RT-PCR or immu-
nohistochemistry. We concentrated our expression analysis
on genes, which up to now have not been reported to be
differentially expressed in pancreatic adenocarcinoma. How-
ever, annexin 1, known for being overexpressed in pancre-
atic cancer, was included. For the putative tumor-suppressor
BBC1, we were able to verify the downregulation observed in
VArasmut cells in samples of pancreatic cancer (Figure 2,
upper panel ). Moreover, also for the gene rhoGDIa, which
Table 1. Primers Used for the RT-PCR of Human Tissue Samples.
Gene Name Primer Sequence Product Size
(bp)
Annexin 1 Forward: 5V-ATGTCGCTGCCTTGCATAA 432
Reverse: 5V-CCTCAGATCGGTCACCCTTA
BBC1 Forward: 5V-GTTCGGTACCACACGAAGGT 480
Reverse: 5V-ACTGCCGACTGATTCCAAGT
rhoGDIa Forward: 5V-TTTCCGCAGACCCCAAC 406
Reverse: 5V-GAGATTCCACTCCCAGGACA
SCART1 Forward: 5V-TACAGCAGCTGCGAGACAGT 222
Reverse: 5V-TCCTCATCCCGTTCAAAGTC
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is overexpressed in VArasmut cells, a trend for an over-
expression in samples of pancreatic adenocarcinoma was
detectable (Figure 2, lower panel ). In contrast, the expres-
sion of the gene squamous cell carcinoma antigen recog-
nized by T cells (SCART1), which was downregulated in
VArasmut cells, was not changed in pancreatic adenocarci-
noma (Figure 2, middle panel ).
The expression of annexin 1 was analyzed in more detail.
At the RNA level, ANX1 expression was barely detectable in
normal pancreatic tissues, and most of the cases of chronic
pancreatitis showed only a slight increase in ANX1 expres-
sion, whereas in one case, the expression was markedly up-
regulated to levels comparable to the expression level
detectable in pancreatic carcinoma (Figure 3). Comparable
results were obtained at the protein level using immunohisto-
chemistry. The staining pattern for ANX1 in CP ranged from
samples with no obvious staining to samples with single
nests of ANX1-positive ductal structures (Figure 4A) and sam-
ples in which the majority of the remaining exocrine tissues
were ANX1-positive (Figure 4C); in one case, nuclear staining
was also observable (Figure 4B). In ductal pancreatic adeno-
carcinoma, tumor cells stained positive (Figure 4D).
Discussion
In the last decades, knowledge concerning the molecular
pathology of pancreatic ductal adenocarcinoma (PDAC) has
Figure 1. Two-dimensional gel electrophoresis of VA and VArasmut cell ly-
sates. Differentially expressed proteins are marked by circles. In the rectan-
gles in the lower panel, the intensities of the respective spots are illustrated in
3D; the region shown corresponds to the rectangles in the upper panel.
Table 2. Putative Homology and Identities of cDNA Differentially Expressed in VArasmut Cells.
Number Expression Change Homology
Base Pairs Submitted
to BLAST
GenBank Accession
Number Identities
Upregulated
1 * Collagen, type I, a 1 534 NM_000088 Human 290/309 (93%)
2 * CK19 gene 454 X04198 Bovine 149/151 (98%)
3 * Keratin 7 320 BC002700 Human 135/146 (92%)
4 * Osteonectin 451 J03233 Bovine 194/195 (99%)
5 y 40-kDa keratin intermediate filament precursor gene 429 J03607 Human 188/204 (92%)
6 y Keratin 18 365 NM_000224 Human 154/176 (87%)
7 y Myosin regulatory light chain 377 D82057 Human 173/185 (93%)
8 z a Enolase mRNA 433 AF149256 Bovine 193/201 (96%)
9 z Clathrin heavy chain 549 U31757 Bovine 283/285 (99%)
10 z EST 336 CB446148 Bovine 207/237 (87%)
11 z EST 360 CB464940 Bovine 180/196 (91%)
12 z Hypothetical protein MGC10731 540 NM_030907 Human 161/185 (87%)
13 z Hypothetical protein MGC2963 700 NM_031298 Human 331/359 (92%)
14 z Mitochondrial ribosomal protein S34 560 NM_023936 Human 312/365 (85%)
15 z Procollagen, type V, a 2 458 XM_193986 Mouse 107/125 (85%)
16 z Ribosomal protein L26 372 AB093679 Primate 112/137 (81%)
Downregulated
1 * Breast basic conserved 1 433 AF192977 Ovine 184/190 (96%)
2 * Ezrin 576 M98498 Bovine 414/415 (99%)
3 * MHC class 1 protein molecule D18.3 463 Y09207 Bovine 266/266 (100%)
4 * Proliferating cell nuclear antigen 550 AF416380 Ovine 304/318 (95%)
5 * Ribosomal protein S5 686 BC018828 Human 275/324 (84%)
6 y ADP/ATP translocase T2 367 M24103 Bovine 159/160 (99%)
7 y Apolipoprotein A-I 520 M35870 Bovine 316/322 (98%)
8 y b Actin 469 AF129289 Ovine 175/186 (94%)
9 y Chromosome 21 open reading frame 59 (C21orf59) 664 NM_021254 Human 433/494 (87%)
10 y Epsin 1 577 NM_057136 Rat 461/515 (89%)
11 y EST 272 BM433009 Bovine 134/142 (94%)
12 y Glioma-tumor-suppressor candidate region gene 2 413 BC013307 Human 199/235 (84%)
13 y Ribosomal protein L30 277 AF063243 Bovine 112/113 (99%)
14 y Squamous cell carcinoma antigen recognized by
T cells 1
537 BC028823 Mouse 264/310 (85%)
15 z EST 443 AV609800 Bovine 226/228 (99%)
16 z EST 575 BE751110 Bovine 469/475 (98%)
17 z EST 523 CB462154 Bovine 309/324 (95%)
18 z Ribosomal protein S19 324 BC018616 Human 145/153 (94%)
*Expression change, > 5-fold.
yExpression change, > 3-fold.
zExpression change, > 2-fold.
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increased markedly. However, this disease still remains an
unresolved problem due to late diagnosis, low resectability,
and the almost complete resistance to conventional radio-
therapy/chemotherapy [10]. Several studies attempted to
identify new diagnostic markers or new therapeutic targets
for PDAC by gene expression microarray analysis of either
bulk tissue [11,12] ormicrodissected pancreatic cancer tissue
[13,14]. These studies have identified a multitude of differ-
entially expressed genes in PDAC and have contributed to
a better understanding of the aggressive behavior of PDAC.
However, there is little overlap of identified genes among
various gene expression studies. Thus, comparison of the
results of several expression studies in PDAC revealed that
148 of 978 [15] and 64 of 568 [16] differentially expressed
genes were identified in at least 2 of 10 studies analyzed. As
discussed in the latter two publications, this low concor-
dance may be due to type, histology, and number of samples
used, or to different platforms and analysis procedures
applied. Moreover, changes at the RNA level do not always
correlate with protein expression [17]; therefore, in the last
years, proteomic approaches have been used to identify
Figure 2. Expression of the genes BBC1, SCART1, and rhoGDIa in nor-
mal pancreas (lanes 1–5) and pancreatic cancer (lanes 6–10), analyzed
using semiquantitative RT-PCR. BBC1 was moderately downregulated and
rhoGDIa was moderately upregulated, whereas for SCART1, no obvious
change in expression level was detectable. The housekeeping gene RPL13A
(lanes 1–5 and 11–15 in Figure 3 correspond to lanes 1–5 and 6–10 in this
figure) was used for normalization. nc = negative control.
Table 3. Results of MALDI-TOF-MS and Database Search for Differentially Expressed Proteins in VArasmut Cells.
Protein Name Taxonomy*
Accession
Number
Mascot
Scorey
Peptides
Matched
Peptide
Coverage (%)
Molecular Weight
Mw (Theoretical/
Experimental; kDa)
pI (Theoretical/
Experimental) VArasmut/VAz ± SD
Keratin type II, cytoskeletal 8 B P05786 239 17 55 42.2/53.3 5.13/5.92 + 3.3 ± 0.3
Stress-induced phosphoprotein 1 M AAH03794 102 10 20 63.2/64.6 6.40/6.27 + 3.0 ± 1.2
Heat shock 70-kDa protein 8 B NP_776770 133 12 24 71.4/71.5 5.49/5.50 + 2.8 ± 0.9
Heat shock 27-kDa protein C P42929 92 7 30 22.9/25.0 6.23/6.11 + 2.6 ± 1.0
Heat shock 70-kDa protein 8 isoform B NP_776770 66 7 12 71.4/71.5 5.49/5.45 + 2.3 ± 0.2
Glucose-regulated protein 58 kDa B NP_776758 280 20 42 57.3/58.6 6.23/6.16 + 2.1 ± 0.4
Annexin 1 B NP_786978 190 13 48 39.1/35.8 6.44/6.39 + 1.9 ± 1.4
Rho GDP dissociation inhibitor a B NP_788823 129 8 37 23.5/26.5 5.12/5.24 + 1.8 ± 0.5
b/g Actin M CAA31455 95 8 26 41.3/44.1 5.56/5.43 + 1.8 ± 1.0
Heat shock 70-kDa protein 5 H NP_005338 147 12 24 72.4/75.2 5.07/5.12 + 1.6 ± 0.2
b Tubulin [fragmented protein] M NP_076205 197 14 27 50.4/36.0 4.78/5.59 + 1.6 ± 0.6
g Actin H AAA51580 81 5 21 26.1/26.1 5.65/5.65  1.6 ± 0.7
a Tubulin [fragmented protein] H NP_116093 93 8 26 50.5/38.3 4.96/5.67  1.8 ± 0.7
Tropomyosin 1 H NP_000357 105 9 25 32.8/31.2 4.81/4.69  1.9 ± 0.8
Keratin, type II cytoskeletal 8
[fragmented protein]
B P05786 115 8 25 42.4/26.4 5.13/5.01  2.0 ± 1.1
Vimentin B NP_776394 187 15 42 53.7/47.7 5.20/4.89  2.1 ± 0.7
b/g Actin B ATBOB 86 6 20 41.9/41.9 5.31/5.29  2.1 ± 1.2
Vimentin B NP_776394 130 11 31 53.7/44.9 5.20/4.68  2.5 ± 0.9
Myosin regulatory light chain H NP_006462 60 4 29 19.8/21.2 4.67/4.60  3.0 ± 0.2
Proliferating cell nuclear antigen M NP_035175 89 6 26 29.1/32.7 4.66/4.60  5.0 ± 0.9
pI = isoelectrical point; SD = standard deviation.
*C = Canis familaris; B = Bos taurus; H = Homo sapiens; M = Mus musculus.
yThe mascot score is measured as 10*log(P), where P is the absolute probability that the observed match is a random event.
zFold change: (+) an increase in protein expression in VArasmut cells; () a decrease in protein expression in VArasmut cells.
Figure 3. Marked upregulation of annexin 1 expression in pancreatic carci-
noma (lanes 11–15) compared to normal pancreas (lanes 1–5) and chronic
pancreatitis (lanes 6–10), analyzed using semiquantitative RT-PCR. The
housekeeping gene RPL13A was used for normalization. nc = negative control.
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differentially expressed proteins in PDAC [18,19]. Taking the
results of these proteomic approaches, only about 20% to
30% of differentially expressed proteins were reflected
by concomitant changes at the mRNA level [20]. However,
these studies, too, showed only little concordance of the re-
sults, probably due to the same factors already discussed for
transcriptomic approaches.
Recently, we have demonstrated that the expression of
a mutated ki-ras oncogene in immortalized pancreatic duct
epithelial cells yielded a tumorigenic transformed phenotype
[6]. Using this in vitro model of pancreatic carcinogenesis,
we sought to overcome some of the problems described
above. First, by the use of two cell lines differing only in the
expression of a mutated ki-ras, a comparison of different cell
types found in pancreatic cancer tissues was avoided.
Moreover, our survey of ras transformation targets should
augment the chance to identify marker molecules with ex-
pression changes early in the course of pancreatic carcino-
genesis, as ki-ras mutations are detectable already in about
40% of PanIN-1 lesions associated with PDAC [5]. Compa-
rable strategies were applied in two studies either by the
inhibition of the expression of a mutated ras using antisense
k-ras–transduced AsPC-1 cells [21] or by the expression of
a mutated k-ras in HPV16-E6E7–immortalized human pan-
creatic duct epithelial cells [22]. Both studies analyzed
differentially expressed genes at the RNA level. In the former
study using the differential display technique, 20 differentially
expressed genes were identified, of which > 50% were
mitochondrial genes. In the latter study using Affymetrix
gene chip arrays, about 1050 differentially expressed genes
induced by the expression of the mutated k-ras gene were
identified. However, only 5% of these genes have been
reported previously as differentially expressed in PDAC or
pancreatic tumor cell lines. To overcome these limitations,
we combined transcriptomic and proteomic techniques in
one study to identify targets with differential expressions both
at the mRNA level and at the protein level. Using this
approach, we identified 28 unique genes and 6 ESTs differ-
entially expressed at the mRNA level using SSH analysis,
and 15 unique differentially expressed proteins using 2D
PAGE and MS analysis. In our study, as in others [17,20],
concordance between mRNA and protein data was only
marginal. Thus, only highly abundant proteins such as actin
and CKs were identified by both techniques. This may be due
to the lower dynamic range of the 2D PAGE protocol, which
allows less abundant proteins to escape detection [23].
However, many of the differentially expressed molecules
identified with either method (14 of 28 genes and 6 of 15
proteins; Tables 2 and 3) already had been demonstrated to
be differentially expressed in pancreatic adenocarcinoma or
to be influenced by a mutated ras, thus proving the validity of
our model. To further validate our model, the expression of
several genes was analyzed by RT-PCR and immunohisto-
chemistry in samples from normal human pancreas, chronic
pancreatitis, and PDAC. For three of four genes analyzed
(BBC1, rhoGDIa, and ANXA1), the trend observed in our
model system was also detectable in PDAC samples, again
proving the validity of our model.
Figure 4. Annexin 1 (ANX1) staining in chronic pancreatitis (A–C) and pancreatic adenocarcinoma (D). The staining pattern for ANX1 in CP ranged from single
nests of ANX1-positive ductal structures (A) to samples in which the majority of the remaining exocrine tissues were ANX1-positive (C); in one case, nuclear
staining was also observable (B). In pancreatic carcinoma, tumor cells stained positive (D).
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Due to the high number of differentially expressed genes
and proteins, only a selected set of these molecules will be
discussed in more detail. The majority of the expression
changes identified affected cytoskeletal proteins. The cyto-
skeleton is involved in numerous cellular functions such as
cell motility, mitogenesis, morphology, muscle contraction,
cytokinesis, and establishment of cell polarity. Deregulated
expression and reorganization of cytoskeletal proteins are
associated with the development of various forms of cancer
[24]. In our study, we found an overexpression at the RNA
level of CKs such as CK7, CK8, and CK19, as well as of
myosin regulatory light chain. Overexpression of these CKs
already has been reported in pancreatic carcinoma in several
other gene expression studies [11,12], and myosin regu-
latory light chain has been shown to be involved in the in-
vasion and adhesion of pancreatic cancer cells [25]. At the
protein level, the results concerning CK expression were
quite different. Here only a translationally modified isoform
of CK8 was detectable, showing an increased apparent mo-
lecular weight compared to the theoretical value, and this
isoform was upregulated in VArasmut cells.
A fragmented form of CK8 and additionally fragmented
forms of the cytoskeletal proteins a tubulin, b tubulin, and
vimentin were identified, which, except for b tubulin, were all
downregulated in VArasmut cells. Although we cannot rule
out that the fragmentation of these proteins happened during
the isolation of the proteins, the other proteins identified in
this study were not fragmented, which argues against this
possibility. Proteolytic degradation of several proteins, in-
cluding nuclear lamins, CKs, and vimentin, is a hallmark of
the dramatic cytoskeletal reorganization that occurs during
apoptosis [26–28]. Caspase-mediated fragmentation of
CK18 and CK19 during apoptosis generated stable frag-
ments with a defined molecular weight (CK18: 29 and
23 kDa; CK19: 28 and 20 kDa), whereas type II CKs (e.g.,
CK8) are virtually resistant to this degradation [27]. Because
CK8 fragments have been detected, caspase-mediated
fragmentation appears not to be the cause of the observed
CK degradation. However, the release of proteolytically
processed CKs (CK8, CK18, and CK19) into the culture
medium was reported for the mammary tumor cell line
MCF-7 [29]. This release of fragmented CKs resulted in
the development of serum tumor markers such as TPS
(CK18 fragment) and CYFRA 21-1 (CK19 fragment) [30].
Although these markers traditionally have been considered as
markers of tumor proliferation, more recently, it has been
shown that these markers are also released during the
apoptosis of epithelial tumor cells [31]. Therefore, the reduced
level of CK8 fragmentation may be an indicator of a reduced
basal apoptotic rate in VArasmut cells.
The a and b tubulin fragments were slightly underrepre-
sented and overrepresented in VArasmut cells, respectively.
In contrast, vimentin fragments were markedly decreased in
VArasmut cells. Like CKs, tubulin [32] and vimentin [33] are
also cleaved during apoptosis. Caspase-mediated proteoly-
sis of vimentin results in the generation of several fragments,
including fragments of about 48 and 45 kDa [28], which were
also identified in our study. Thus, the decreased fragmenta-
tion of a tubulin and vimentin again indicates a reduced basal
rate of apoptosis in VArasmut cells.
Another large group of proteins with altered expression
consisted of HSPs and cochaperones. All of these proteins
(HSP70, HSP27, Grp58, and stress-induced phosphoprotein
1, also called HSP70/HSP90 organizing protein/HOP) were
upregulated in VArasmut cells. HSPs were discovered as a
group of proteins that are induced by various kinds of stress
[34]; they facilitate the correct folding of other proteins under
physiological and stress conditions with the help of co-
chaperones such as HOP [35]. Overexpressed HSP27 and
HSP70 prevent the apoptosis induced by various stimuli,
including hyperthermia, oxidative stress, CD95 ligation, or
chemotherapy, by interfering with the action of key apoptotic
proteins, such as Bid, Bax, apoptosis-inducing factor, and
apoptosis protease–activating factor 1. Moreover, the sig-
naling of survival factors through the PI3K/Akt pathway is
promoted by the binding of HSP27 to Akt (reviewed in
Garrido et al. [36]). HSPs are overexpressed in various forms
of cancer, such as breast cancer [37], gastric cancer [38],
colorectal carcinoma [39], and pancreatic carcinoma [40].
HSP27 and HSP70 expressions are associated with the
invasion and metastasis of xenotransplanted human breast
cancer cells [41] and with an increase in the tumorigenic
potential of a mouse fibrosarcoma model [42], respectively.
Increased HSP27 and HSP70 expression in acute myeloid
leukemia, esophageal carcinomas, and colonic cancers has
been associated with poor prognosis [43], resistance to
radiotherapy and chemotherapy [44], and metastasis [45].
In contrast, pancreatic carcinoma patients with extensive
HSP70 staining of tumor cells had a better prognosis [46].
In normal cells, the chaperone Grp58, a member of the
protein disulfide isomerase family, is an integral part of the
peptide-loading complex of the MHC class I molecules [47]
and also is implicated in signaling by Stat3 [48]. Expression
of Grp58 was induced in v-onc–transformed and v-src–
transformed kidney cells and fibroblasts, respectively [49].
Additionally, overexpression of Grp58 was associated with
chemoresistance in oral squamous cell carcinoma [50] and
serous epithelial ovarian carcinoma [51]. However, inhibition
of Grp58 expression by siRNA decreased mitomycin C–
induced cytotoxicity in human colon carcinoma cells [52].
Thus, the increased expression of HSPs, HOP, and Grp58
observed in VArasmut cells may confer an increased resis-
tance to apoptosis in cells. The resulting reduced apoptotic
rate could be reflected by the observed reduced fragmenta-
tion of cytoskeletal proteins, as discussed above.
Two putative tumor-suppressor genes, GLTSCR2 and
BBC1, were downregulated in ki-ras–transfected cells. Re-
cently, the stabilization of the tumor-suppressor PTEN by the
protein PICT-1, encoded byGLTSCR2, was demonstrated in
human breast cancer MCF-7 cells [53]. Thus, the reduced
expression of GLTSCR2 may explain the loss of PTEN
observable in pancreatic cancer cells without concomitant
mutation or promoter methylation of the PTEN gene [54,55].
The gene BBC1 located on chromosome 16 was originally
described as a putative breast-tumor-suppressor gene [56].
Allelic loss of the chromosome region of BBC1 (16q22–q24)
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was associated with sporadic breast cancer [57]. However, in
a later study, no tumor-specific mutations in the BBC1 gene
were detected in a selected set of breast tumors that showed
loss of heterozygosity (LOH) at 16q24, thus excluding BBC1
as a candidate breast-tumor-suppressor gene [58]. Also in
prostate cancer, several studies demonstrated LOH of the
BBC1 region in prostatic cancer [59,60], which increased in
higher-grade tumors and metastases. Up to now, only one
publication has reported a loss of the chromosomal region of
BBC1 (16q22–q24) in pancreatic cancer [61], and in our
small series of five pancreatic adenocarcinoma samples, a
clear trend toward a reduced BBC1 expression was detect-
able, encouraging further studies on BBC1 as a tumor-
suppressor gene in PDAC.
rhoGDIa is a cellular regulatory protein that acts primar-
ily by controlling the cellular distribution and activity of rho
GTPases [62], which transduce external signals to multiple
downstream targets to elicit a variety of cellular responses
such as organization of the actin cytoskeleton, cell cycle
progression, cell polarity, and morphology [63]. GDIs typi-
cally act as negative regulators of rho GTPases through
inhibition of GDP–GTP exchange [64]. Nevertheless, it has
been demonstrated that rhoGDI, despite being a negative
regulator of Cdc42 activation, is required for Cdc42-mediated
cellular transformation [65]. Moreover, rhoGDI is over-
expressed in a variety of cancers such as ovarian cancer
[66], breast cancer [67], and lung cancer [68]. To our knowl-
edge, except for the present study, there is only one additional
publication concerning the overexpression of rhoGDIa in
PDAC [69]. Additionally, rhoGDI overexpression is asso-
ciated with chemoresistance in ovarian cancer [70], breast
cancer [71], and melanoma [72]. Given the almost complete
resistance of PDAC to conventional chemotherapy, the role
of rhoGDIa overexpresson in pancreatic cancer warrants
further analysis.
The protein annexin 1 was found to be overexpressed in
VArasmut cells. Annexin 1, also called lipocortin 1, belongs to
a large family of Ca2+-dependent phospholipid-binding pro-
teins [73]. It is a glucocorticoid-regulated protein and shares
many anti-inflammatory effects with these drugs, such as
inhibition of cell proliferation, regulation of cell migration, and
apoptosis [74,75]. Overexpression of annexin 1 has been
reported for various cancers such as breast cancer [76] and
hepatocellular carcinoma [77]. However, its downregulation
was found, for example, in esophageal and prostate carci-
noma [78]. In pancreatic carcinoma, overexpression of
annexin 1 was demonstrated at the RNA level [12,14] and
at the protein level [19] and correlated with a poorly differ-
entiated phenotype of tumor cells [79]. Increased annexin 1
expression was demonstrated in drug-resistant tumor cells
of the stomach [80], prostate [81], and breast [82]. Thus,
the overexpression of annexin 1 may be responsible, at least
in part, for the chemoresistance found in virtually all pan-
creatic carcinomas.
In conclusion, we have demonstrated that the transfec-
tion of a mutated ki-ras was accompanied by a specific ex-
pression pattern of several genes and proteins, which
may result in an increase in malignant potential and an in-
creased resistance to the apoptosis of transfected VArasmut
cells. Thus, our in vitro model is a valuable tool that may
be used to analyze the role of genetic alterations implicated
in the early stages of tumor development in PDAC. The
combination of two different approaches studying gene ex-
pression, namely, transcriptomics and proteomics, allowed
for the identification of potential targets for the early diagno-
sis and/or therapy of pancreatic carcinoma, whereas these
targets would have been missed by using only one of these
two techniques.
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